HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells

Virology

Volumn 407, Issue 1, 2010, Pages 137-142

  Campo, M S ^a   Graham, S V ^a   Cortese, M S ^a   Ashrafi, G H ^a   Araibi, E H ^a   Dornan, E S ^a   Miners, K ^b   Nunes, C ^b   Man, S ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CD8 T cells; HLA down regulation; HPV 16 E5; Immuno evasion; W12

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; ONCOGENE PROTEIN E5, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; BIOSYNTHESIS; FLOW CYTOMETRY; IMMUNE EVASION; IMMUNOLOGY; MOUSE; PATHOGENICITY; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DOWN-REGULATION; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; MICE; ONCOGENE PROTEINS, VIRAL;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 77956931304     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.07.044     Document Type: Article

References (28)

1. Aasen T., Hodgins M.B., Edward M., Graham S.V. The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression. Oncogene 2003, 22:7969-7980.
2. Alazawi W., Pett M., Arch B., Scott L., Freeman T., Stanley M.A., Coleman N. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res. 2002, 62(23):6959-6965.
3. Araibi, E.H. (2006). Down-regulation of MHC class I by papillomavirus E5 proteins. PhD Thesis, University of Glasgow.
4. Araibi E.H., Marchetti B., Ashrafi G.H., Campo M.S. Down-regulation of MHC class I in bovine papillomas. J. Gen. Virol. 2004, 85:2809-2814.
5. Araibi E.H., Marchetti B., Dornan E.S., Ashrafi G.H., Dobromylskyj M., Ellis S.A., Campo M.S. The E5 oncoprotein of BPV-4 does not interfere with the biosynthetic pathway of non-classical MHC class I. Virology 2006, 353(1):174-183.
6. Ashrafi G.H., Tsirimonaki E., Marchetti B., O'Brien P.M., Sibbet G.J., Andrew L., Campo M.S. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002, 21(2):248-259.
7. Ashrafi G.H., Haghshenas M.R., Marchetti B., O'Brien P.M., Campo M.S. The E5 protein of human papillomavirus type 16 selectively down-regulates surface HLA class. Int. J. Cancer 2005, 113:276-283.
8. Ashrafi G.H., Haghshenas M.R., Marchetti B., Campo M.S. E5 protein of human papillomavirus 16 down-regulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 2006, 119(9):2105-2112.
9. Cortese M.S., Ashrafi G.H., Campo M.S. All four di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I down-regulation activity and E5 endomembrane localisation. Int. J. Cancer 2010, 126:1675-1682.
10. Ellis S.A., Holmes E.C., Staines K.A., Smith K.B., Stear M.J., McKeever D.J., MacHugh N.D., Morrison W.I. Variation in the number of expressed MHC genes in different cattle class I haplotypes. Immunogenetics 1999, 50:319-328.
11. Evans M., Borysiewicz L.K., Evans A.S., Rowe M., Jones M., Gileadi U., Cerundolo V., Man S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 2001, 167(9):5420-5428.
12. Jeon S., AllenHoffmann B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 1995, 69:2989-2997.
13. Kenter G.G., Welters M.J.P., Valentijn A.R.P.M., Lowik M.J.G., Berends-van der Meer D.M.A., Vloon A.P.G., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., van der Burg S.H., Melief C.J.M. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J. Med. 2009, 361(19):1838-1847.
14. Knowles G., O'Neil B.W., Campo M.S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J. Virol. 1996, 70(12):8451-8458.
15. Lilley B.N., Ploegh H.L. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol. Rev. 2005, 207:126-144.
16. Marchetti B., Ashrafi G.H., Tsirimonaki E., O'Brien P.M., Campo M.S. The papillomavirus oncoprotein E5 retains the major histocompatibility class I in the Golgi apparatus and prevents its transport to the cell surface. Oncogene 2002, 21:7808-7816.
17. Marchetti B., Gault E.A., Cortese M.S., Yuan Z.Q., Ellis S.A., Nasir L., Campo M.S. Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J. Gen. Virol. 2009, 90:2865-2870.
18. McPhillips M.G., Veerapraditsin T., Cumming S.A., Karali D., Milligan S.G., Boner W., Morgan I.M., Graham S.V. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J. Virol. 2004, 78:10598-10605.
19. Nicholls P.K., Moore P.F., Anderson D.M., Moore R.A., Parry N.R., Gough G.W., Stanley M.A. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001, 283(1):31-39.
20. O'Brien P.M., Campo M.S. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 2002, 1-2:103-118.
21. Schapiro F., Sparkowski J., Adduci A., Suprynowicz F., Schlegel R., Grinstein S. Golgi alkalinization by the papillomavirus E5 oncoprotein. J. Cell Biol. 2000, 148(2):305-315.
22. Selvakumar R., Schmitt A., Iftner T., Ahmed R., Wettstein F.O. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression. J. Virol. 1997, 71(7):5540-5548.
23. Stanley M.A., Pett M.R., Coleman N. HPV: from infection to cancer. Biochem. Soc. Trans. 2007, 035(6):1456-1460.
24. 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int. J. Cancer 2008, 122(12):2791-2799.
25. Tomasec P., Braud V.M., Rickards C., Powell M.B., McSharry B.P., Gadola S., Cerundolo V., Borysiewicz L.K., McMichael A.J., Wilkinson J.W. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287:1031.
26. Valitutti S., Müller S., Dessing M., Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 1996, 183:1917-1921.
27. Youde S.J., McCarthy C.M., Thomas K.J., Smith K.L., Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int. J. Cancer 2005, 114:606-612.
28. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384(2):260-265.